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ENGLISH SUMMARY 
Although the primary treatment for Crohn’s disease (CD) is medical, more than half 
of patients with Crohn’s disease will require surgery at some point during their 
lifetime. The risk of surgery at 1, 5, and 10 years after the diagnosis of CD is 16.3%, 
33.3%, and 46.6%, respectively. The advent of anti-TNF-α agents has caused a 
therapeutic paradigm shift in the treatment of CD: the goal has changed from the 
management of disease flare-ups using immunosuppressive agents to the achievement 
of complete remission of the inflammatory state. However, the inhibition of TNF-α 
by anti-TNF-α agents might impair surgical wound healing and thus increase the rate 
of postoperative complications. There is therefore a need to investigate this risk in 
depth. 
 
Aim 
The aim of this thesis was to investigate the effect of treatment with anti-TNF-α agents 
on the postoperative outcome in patients with CD undergoing bowel resection. 
 
Methods 
Study 1 was a retrospective cohort multi-centre study using data collected from the 
hospital registry. The primary outcome was anastomosis-related complications or 
intra-abdominal septic complications (IASC) defined as overt anastomotic 
dehiscence, enteric fistula, or intra-abdominal abscess requiring treatment with 
laparotomy, laparoscopy or percutaneous radiologically guided drainage, and the 
secondary outcome variables were postoperative septic complications and other 
complications.  
Study 2 constituted a systematic review and meta-analysis based on a predefined study 
protocol that was developed and reported according to the recommendations in the 
Cochrane Handbook for Reviews of Interventions and the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement. Electronic searches 
of MEDLINE, EMBASE, and the Cochrane Library were performed. The primary 
outcome measure was anastomotic complications, including overt anastomotic leak 
(dehiscence), intra-abdominal abscess or enteric fistula verified by radiological 
imaging, laparotomy or laparoscopy. The secondary outcome measures were the total 
number of complications, non-anastomotic surgical complications, infectious 
complications, major medical complications, minor medical complications, 
reoperation and mortality.  
Study 3 investigated the differences in reviews and meta-analyses regarding the 
effects of anti-TNF-α on postoperative outcome. This narrative systematic review 
included a literature search similar to that used in study 2 of this thesis. The primary 
outcome measure was 30-day postoperative complications.  
Study 4 was a prospective, observational multi-centre cohort pilot study of the surgical 
stress response in patients with inflammatory bowel disease and investigated the 
effects of anti-TNF-α agents on the surgical stress response. The primary outcome 
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was the change in the concentration of immunological biomarkers of the surgical 
stress response (TNF-α, IL-6, and IL-10), and the secondary outcome measures were 
changes in IL-8, IL-17A, C-reactive protein, white blood cells, cortisol, transferrin, 
ferritin, and D-dimer, 30-day postoperative complications and length of postoperative 
stay in the hospital. 
 
Results 
The results of the first study showed that preoperative treatment with anti-TNF-α or 
immunomodulators does not affect the incidence of anastomotic complications, but 
other studies on the subject reached different conclusions. The study also confirmed 
previous findings that corticosteroids and colocolic anastomosis are associated with 
postoperative complications. 
These findings stimulated an extensive search to find and pool all the available studies 
on the effect of anti-TNF-α agents on postoperative outcome. The subsequent meta-
analysis of the identified studies concluded that in studies with a low risk of bias, anti-
TNF-α agents increased the risk of anastomotic complications. Several meta-analyses 
on the topic have been published, and these yielded divergent results. Study 3 
explained the reasons for the controversial findings of these meta-analyses. Meta-
analyses with large numbers of patients and a quality assessment revealed that patients 
receiving anti-TNF-α treatment are at increased risk of overall postoperative 
complications. 
Study 4 was designed based on the above-mentioned knowledge. This study showed 
no effect of anti-TNF-α treatment on the surgical stress response. However, the study 
also showed a wide variation in the type, dose, and duration of treatment, the drug 
concentration and the presence of anti-drug antibodies in patients who received anti-
TNF-α agents during the 12 weeks prior to the operation. This variation might explain 
the conflicting results of retrospective studies regarding the effect of anti-TNF-α 
treatment. 
 
Conclusion 
The effect of anti-TNF-α therapy on the postoperative outcome in patients with CD 
results from an interplay of many factors. Some of the most important factors include 
concomitant steroid therapy, disease severity, nutritional status, smoking, 
preoperative optimization, preoperative drug concentration and the presence of anti-
drug antibodies. Preoperative withdrawal of anti-TNF-α is not supported by the 
current evidence, but a multi-centre randomized controlled trial is needed to confirm 
or disprove this practice. 
 
  
DANSK RESUME
Patienter med Crohns sygdom behandles som standard medicinsk, men mere end 
halvdelen af patienterne vil have brug for kirurgisk behandling en eller flere gange i 
løbet af deres levetid. Sandsynligheden for større abdominal kirurgi er henholdsvis 
16.3%, 33.3% og 46.6% henholdsvis 1, 5, og 10 år efter diagnosen er stillet. 
Udviklingen af anti-TNF- α -lægemidler har medført et terapeutisk paradigmeskifte i 
behandlingen af Crohns sygdom. Målet har ændret sig fra håndtering af sygdommens 
opblussen med immunosuppressive lægemidler til opnåelse af fuld remission af den 
inflammatoriske tilstand. Studier har dog indikeret, at hæmning af TNF- α muligvis 
kan influere på kirurgisk sårheling og således øge risikoen for postoperative 
komplikationer. Der er derfor et behov for yderligere undersøgelser af denne risiko. 
Formål 
Formålet med denne afhandling er at undersøge effekten af anti-TNF-α lægemidler på 
postoperative outcomes hos patienter med Crohns sygdom, der gennemgår 
tarmresektion. 
Metoder 
Afhandlingen er baseret på fire studier:  
Studie 1 er en retrospektiv multi-center undersøgelse. Data er indsamlet ved brug af 
hospitalsregistre. Det primære outcome er anastomose-relaterede komplikationer eller 
intra-abdominale septiske komplikationer (IASC), defineret som åbenlys anastomose 
lækage, enterisk fistel eller intra-abdominal absces, der kræver behandling med 
laparotomi, laparoskopi eller perkutan radiologisk vejledt drænage. De sekundære 
outcomes er postoperativ septisk komplikation og andre komplikationer. 
Studie 2 er en systematisk gennemgang og meta-analyse baseret på en foruddefineret 
studieprotokol udviklet og rapporteret i overensstemmelse med anbefalingerne i 
Cochrane ”Handbook for reviews of Interventions” og ”Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses” (PRISMA) erklæringen. De elektroniske 
søgninger blev udført i MEDLINE, EMBASE og Cochrane Library. Det primære 
outcome er anastomotiske komplikationer (AC), herunder anastomose lækage, intra-
abdominale abscesser eller enteriske fistler, der blev verificeret gennem radiologisk 
billeddannelse, laparotomi eller laparoskopi. De sekundære outcomes er det samlede 
antal komplikationer, ikke-anastomose relaterede kirurgiske komplikationer, 
infektiøse komplikationer, større medicinske komplikationer, mindre medicinske 
komplikationer, re-operation og dødelighed. 
Studie 3 undersøger forskellene i review og meta-analyser for effekten af anti-TNF-α 
lægemidler på postoperative outcomes. Undersøgelsen er en systematisk gennemgang 
uden statistisk analyse. Den litteratursøgning, der blev anvendt, var den samme som i 
studie 2. Det primære outcome er 30 dages postoperative komplikationer. 
Studie 4 er et prospektivt, observationelt multi-center pilot studie. Det beskriver det 
kirurgiske stressrespons hos IBD-patienter og undersøger effekten af anti TNF-α 
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lægemidler på kirurgisk stressrespons. Det primære outcome er ændringen i 
koncentrationen af immunologiske biomarkører for det kirurgiske stressrespons 
(TNF-α, IL-6 og IL-10). De sekundære outcomes er ændringer i IL-8, IL-17A, C-
reaktivt protein, hvide blodlegemer, cortisol, transferrin, ferritin og D-Dimer foruden 
lægemiddelkoncentrationen og antistoffer mod lægemidlet i blodbanen samt 30 dages 
postoperative komplikationer og længden af postoperativ ophold på hospitalet. 
Resultater 
Studie 1 viser, at præoperativ behandling med anti-TNF-α eller andre 
immunmodulerende lægemidler ikke har nogen indflydelse på anastomose-relaterede 
komplikationer. Det er imidlertid påfaldende, at andre studier om emnet kom frem til 
modsatrettede konklusioner med hensyn til behandling med anti-TNF-α lægemidler. 
Undersøgelsen bekræfter desuden tidligere fund; at corticosteroider og kolo-koliske 
anastomoser er associeret med postoperative komplikationer. 
Studie 2 viser, at effekten af anti-TNF-α lægemidler på postoperative outcomes ifølge 
litteraturen varierer, men at TNF-α lægemidlerne øger risikoen for anastomotiske 
komplikationer i studier med lav risiko for bias. Flere meta-analyser om emnet er 
blevet publiceret med tvetydige resultater.  
Studie 3 forklarer dette ved at vise, at meta-analyser, der inkluderer et stort antal 
patienter og anvender kvalitetsvurdering, viser en øget risiko for overordnede 
postoperative komplikationer hos patienter, der har modtaget behandling med anti-
TNF- α lægemidler. 
Studie 4 viser ikke nogen effekt af anti-TNF-α behandling på kirurgisk stressrespons. 
Undersøgelsen viser dog en stor variation i typen, dosen, behandlingsvarigheden, 
lægemiddelkoncentrationen og tilstedeværelse af anti-lægemiddelantistoffer hos 
patienter, der har modtaget anti-TNF-α lægemidler inden for 12 ugers før kirurgi. 
Dette kan måske forklare de modsatrettede konklusioner i de øvrige studier i den 
eksisterende faglitteratur. 
 
Konklusion 
Effekten af anti-TNF-α behandling på det postoperative resultat hos patienter med 
Crohns sygdom er en kombination af mange faktorer. Blandt de vigtigste er 
steroidbehandling, sygdomshyppighed, ernæringsstatus, rygning, præoperativ 
optimering, præoperativ lægemiddelkoncentration og tilstedeværelsen af antistoffer 
mod lægemidler. Derfor kan et behov for præoperativ pausering af anti-TNF-α ikke 
begrundes ud fra det eksisterende vidensgrundlag. Der er behov for en multi-center 
randomizeret kontrolleret undersøgelse for at bekræfte eller afvise dette.  
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1. INTRODUCTION 
1.1 CROHN’S DISEASE  
1.1.1 DEFINITION, INCIDENCE AND PREVALENCE  
Crohn’s disease (CD) is a relapsing systemic inflammatory disease that mainly affects 
the gastrointestinal tract (GT). Extra-intestinal manifestations may present with or 
without the gastrointestinal symptoms.  
The incidence of Crohn’s disease is increasing and is currently estimated to be 6-
15/100,000, whereas its prevalence is 50-200/100,000. The peak age of CD 
occurrence is 20-30 years, and the frequency of CD is 20-30% higher in women1. The 
disease shows a north-south gradient in terms of residence latitude, with a higher 
incidence of CD in northern compared with southern latitudes2. Recent studies have 
also shown an increased incidence of CD in previously low-risk countries, probably 
due to the adoption of a western lifestyle, as in the case of immigrants to western 
countries.  
1.1.2 THE PATHOGENESIS OF CROHN’S DISEASE 
CD is thought to result from an inappropriate inflammatory response to the gut 
microbial flora in genetically predisposed individuals3,4.  
 
The influence of genetics in CD has been shown in epidemiological studies that 
demonstrated different prevalences in different ethnic groups (higher risk of CD in 
Jews, particularly Ashkenazi Jews), familial aggregations (having a relative with CD 
increases the risk of developing CD) and concordance in twins (the rates of 
concordance in monozygotic and dizygotic twins are 30.3% and 3.6%, respectively). 
Genetic studies have identified 163 associated genes/loci, most of which are shared 
between CD and ulcerative colitis (UC); however, some of these genes/loci are also 
associated with other immune-related diseases5. Although inflammatory bowel 
disease (IBD) is currently classified into CD and UC, recent data suggest the 
existence of three genetically distinct groups of diseases (ileal CD, colonic CD and 
UC)6. However, CD and UC have no single highly penetrant genetic cause7. The 
identified genes/loci predispose individuals to CD by affecting the mechanism 
regulating the maintenance of GT homeostasis. 
 
The maintenance of GT homeostasis is critically dependent on the capacity of the 
immune system to remain tolerant to harmless dietary and gut microbial flora-
derived antigens while maintaining the ability to generate protective immune 
responses against harmful intestinal pathogens. This identification involves pattern 
recognition receptors (PRRs). The host possesses a variety of PRRs, including 
membrane-bound toll-like receptors (TLRs) and the cytoplasmic nucleotide-binding 
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oligomerisation domain (Nod)-like receptor (NLR). Genes/loci can affect these 
PRRs to induce the immune system to mount attacks on harmless commensal 
microorganisms.  
The mechanism through which the immune system mounts these attacks remains 
under investigation but might be related to the stimulation of innate immune cells to 
produce proinflammatory cytokines and thereby facilitate further recruitment of 
innate immune cells. NOD signalling can also enhance the production of reactive 
oxygen species (ROS) by innate immune cells. Microbiota play an essential role in 
the reduction and oxidation states of the GT. 
The composition of the microbiota and its interaction with the host can promote the 
development of IBD or trigger disease flares in patients with IBD. Environmental 
factors can trigger IBD in different ways, one of which involves changing the 
composition of the GT microbiota. How the gut microbiota and the immune system 
initiate the inflammatory process in genetically predisposed individuals is not yet 
fully understood. However, a three-stage model (figure 1) was proposed by Sewell 
et al. to explain the pathogenesis of CD4: 
Stage 1: Penetration of luminal contents into the bowel wall, resulting in access to the 
underlying bowel tissues4.  
Stage 2: Impaired clearance of foreign material from the bowel wall, probably due to 
a defect in the secretion of proinflammatory cytokines by macrophages.  
Stage 3: Compensatory adaptive immune responses that occur when the remaining 
uncleared debris is phagocytosed by macrophages, which leads to the formation of 
granulomata. Macrophage activation then results in a ‘second wave’ of secretion of 
proinflammatory cytokines and chemokines that drives the recruitment of T cells to 
the site and their polarization to the characteristic Th1 phenotype4.  
In healthy individuals, the T-cell population is regulated by apoptosis. Defective 
apoptosis thus seems to be a relevant pathogenic mechanism in CD. Most agents used 
for the treatment of IBD, including steroids, sulfasalazine, IFX, azathioprine, 
methotrexate, cyclosporine, tacrolimus and thalidomide, can induce the apoptosis of 
monocytes or lymphocytes. Different molecular apoptotic pathways appear to be 
activated by different drugs, and these pathways might explain the differential 
therapeutic effects of these agents8. 
Tumour necrosis factor alpha (TNF-α) plays an important role in all three stages 
described above and might explain the high TNF-α levels observed in patients with 
CD. In stage 1, TNF-α regulates the intestinal permeability by mediating tight
junctions between intestinal epithelial cells9. It also regulates the secretion of mucin,
which is crucial for the barrier function10. TNF-α is essential for the differentiation
and proliferation of macrophages (stage 2) and plays a key role in the maturation,
proliferation, differentiation and survival of T lymphocytes that occur in stage 3.
Dysregulated TNF signalling might therefore cause aberrant immune T-cell function,
leading to the onset of chronic inflammation. The structure and function of TNF-α are
explained in the following section.
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1.2 TNF-ALPHA 
1.2.1 STRUCTURE AND MECHANISM OF ACTION OF TNF-
ALPHA 
TNF-α is a low-molecular-weight protein that mediates cell-to-cell communication. It 
is produced primarily by activated monocytes and macrophages in response to a 
variety of stimuli11,12.  
TNF-α is recognized by two receptors: TNF-𝛼 receptor-1 (TNF-𝛼R-1), which is 
ubiquitously expressed in nucleated cells, and TNF-𝛼R-2, which is expressed mainly 
in immune cells11,12,13. TNF-α is very potent, and an occupancy of its receptors as low 
as 5% produces a biochemical response14,15. After binding to its receptor, TNF-α 
activates a variety of intracellular signalling pathways that affect gene transcription16. 
TNF-α that is inserted into the cell membrane (mTNF-α) is cleaved by the matrix 
metalloprotease TNF-converting enzyme into a soluble form (sTNF-α). Both sTNF-α 
and mTNF-α are biologically active and can bind to and signal through TNF 
receptors17,8,18.   
TNF-α mediates apoptosis, survival, differentiation and proliferation through the 
activation of different pathways involving nuclear factor kappa B (NF-κB), Janus 
kinase/signal transducer and activator of transcription (JAK/STAT), p42/p44 
mitogen-activated protein kinase (MAPK) and p38 MAPK (figure 2). The activation 
of specific signalling pathways depends on multiple costimulatory intra/extracellular 
factors 11,12,13,19. In addition to its action on effector cells (forward signalling), mTNF-
α also functions as a cellular receptor in TNF-α-producing cells, resulting in “reverse 
signalling”. Through this process, the membrane-integrated ligands can receive 
signals, acting as receptors that transmit positive and negative feedback signals to the 
ligand-bearing cell17,20,21. TNF-α, which is barely detectable in quiescent cells, 
orchestrates inflammatory processes by switching on a TNF-dependent cytokine 
cascade in an autocrine and paracrine manner17. This activation leads to a variety of 
effects that are examined in detail in the next section.  
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    Figure 1: Suggested three-stage theory for the pathogenesis of Crohn’s disease. The 
first stage is initiated by penetration of the luminal contents into the bowel wall 
due to defects in tight junctions. In the second stage, impaired clearance of foreign 
material from the bowel wall leads to compensatory adaptive immune responses 
and the formation of granulomas, triggering the secretion of proinflammatory 
cytokines in stage three. From Sewell 2009, Current Opinion in Immunology (with 
permission from Elsevier). 
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1.2.2 PHYSIOLOGICAL EFFECTS AND FUNCTIONS OF TNF-
ALPHA 
TNF-α stimulates the hypothalamic-pituitary-adrenal axis (HPAA), and this 
stimulation induces the release of corticotropin-releasing hormone (CRH), followed 
by the secretion of steroids that regulate many bodily functions, including the stress 
response. The secretion of C-reactive protein (CRP) by hepatocytes, the chemotaxis 
of neutrophils and the regulation of dendritic cell and macrophage functions are only 
a few of the known functions of TNF-α12. The dose-related role of TNF-α in wound 
healing19,22,23,24 is crucial and will therefore be explained in detail. 
 
Disruption of the protective skin barrier activates an orchestrated cascade of events 
involving growth factors, cytokines and chemokines, leading to wound healing 
through a process that can be divided into three overlapping phases:  
(i) Inflammatory phase: TNF-α stimulates neutrophil and macrophage activity and 
recruitment to the site of injury (chemotaxis)25,26,27. It also stimulates the production 
of other cytokines, such as IL-1 and IL-6, both of which are important during the 
wound healing process28. 
(ii) Proliferative phase: The process of angiogenesis, proliferation and re-
epithelialization is triggered by ROS released secondary to damage to the blood 
vessels25.  TNF-α is essential in this process. 
(iii) Tissue remodelling: TNF-α can inhibit or stimulate collagen synthesis by 
fibroblasts. The effect depends on the concentration of TNF-α in the tissue26,28,29. 
Physiological release of TNF-α following injury is therefore essential for proper 
healing and timely recovery24,29–31. In contrast, the inhibition of TNF-α is essential for 
preventing the effects of overproduction, and this inhibition can be achieved via 
various regulatory feedback mechanisms, as follows32: 
1. sTNFR: Soluble TNF-α receptors compete with cellular receptors for the binding 
of free TNF-α in response to excessive systemic TNF-α activity15,19.  
2. Glucocorticoids: Glucocorticoids were the first identified inhibitors of TNF-α 
production.  
3. Prostaglandin E2: This lipid, which is produced during inflammation, effectively 
switches off TNF-α synthesis.  
4. IL-10 and the IL-10 family: This family consists of the prototypic “anti-
inflammatory cytokines” that inhibit TNF production in vitro and in vivo.  
5. Cholinergic anti-inflammatory pathway: The inhibition of TNF synthesis is 
mediated by acetylcholine acting on macrophages.  
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    Figure 2: Activation of different pathways by TNF-α upon binding to TNF-α 
receptors. The propensity for the activation of each pathway depends on multiple 
co-stimulatory intra- and extracellular factors. NF-κB: nuclear factor kappa B; 
JAK/STAT: Janus kinase/signal transducer and activator of transcription; 
MAPK: mitogen-activated protein kinase. From Wertz 2014, Current Opinion in 
Chemical Biology (with permission from Elsevier). 
Patients with CD who have high TNF-α levels in their lamina propria might exhibit a 
disturbance of feedback regulatory mechanisms. TNF-α is believed to play a role in 
the initiation and amplification of the mucosal inflammatory cascade in CD20,33,3435. 
Microbial products constantly stimulate the production of TNF-α by triggering TLRs 
and NOD-2 PRRs. Depending on the dose and the presence of secondary signals, 
TNF-α can induce either protective or destructive effects on tight junctions36. Leaky 
junctions permit the access of microbial products to underlying intestinal tissue. This 
exposure initiates an inflammatory cascade that is regulated by many mediators, one 
of which is TNF-α, which exerts its action through T-cell apoptosis. The blockage of 
TNF-α can halt or even reverse this process, as discussed in the next section.  
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1.3. ANTI-TNF-ALPHA AGENTS 
1.3.1 TREATMENT STRATEGIES 
Inactivation of TNF-α can be achieved in two ways: the use of monoclonal antibodies 
(mAbs) (for instance, IFX) that bind to TNF-α, and the use of fusion proteins that bind 
to TNF receptors (for instance, Etanercept). Both methods inactivate TNF-α and 
prevent TNF-α-mediated inflammatory processes. The use of anti-TNF-α has changed 
the classical approach for the treatment of CD, which aimed to manage disease flare-
ups using immunosuppressive agents. Anti-TNF-α might result in complete remission 
of the inflammatory state, avoiding the use of steroids, which would improve the 
patient’s quality of life and work productivity and reduce the need for hospitalization 
and surgery37,38. However, many population-based studies have not shown this 
effect39–41. 
The conventional approach for the management of active CD is based on the 
progressive intensification of therapy (“step-up”) as the disease worsens: this therapy 
starts with 5-ASA, steroids, and immunomodulators, and the use of anti-TNF-α is 
reserved for severe or non-responding cases. However, there is a growing consensus 
that the ultimate goal of CD management must be complete disease control and not 
merely clinical improvement. Based on this goal, key therapeutic outcomes have 
moved beyond the control of clinical symptoms to include steroid-free remission and 
mucosal healing (endoscopic remission), which usually leads to a significantly better 
clinical outcome and a significantly improved quality of life42. A top-down approach 
to medical therapy is increasingly being adopted for patients with risk factors for 
severe inflammation or an unfavourable disease course in an attempt to halt the 
inflammatory process at the earliest possible stage. Patients with mild-to-moderate 
inflammation and fewer risk factors may benefit from an accelerated step-up 
approach. Different types of anti-TNF-α are used in the above-mentioned approaches, 
these drugs can be switched in the case of a lack of response or allergic reaction. The 
structure and pharmacokinetics of the currently available anti-TNF-α agents are 
discussed in the next section. 
1.3.2 STRUCTURE AND PHARMACOKINETICS 
Four anti-TNF-α biological agents are currently approved for the treatment of IBD 
(figure 3). Infliximab (IFX) (Remicade® and its two biosimilars, Inflectra® and 
Remsima®), adalimumab (ADA) (Humira®) and golimumab (Simponi®) are bivalent 
monoclonal antibodies, and certolizumab pegol (CZP) (Cimzia®) is a PEGylated 
monovalent Fab antibody fragment16. The drug structures are illustrated in (figure 
3).  
IFX (Remicade®) is a chimeric mAb comprising human and murine variable 
regions, and this mAb is administered via the intravenous (IV) route. The use of this 
route allows the administration of large volumes and results in a more rapid central 
distribution with a low variability in bioavailability compared with subcutaneous 
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(SC) administration, which might be associated with some problems. The induction 
and maintenance dose of IFX for both UC and CD patients is 5 mg/kg every 8 
weeks.  
Figure 3: Structures of anti-TNF-α agents. The figure illustrates the labelling of these monoclonal 
antibodies according to the human and murine variables in their structures. From Baumgart 2007, 
the Lancet (with permission from Elsevier). 
ADA (Humira®) is a human IgG1 mAb that was derived through phage display and is 
administered via the SC route at a dose of 40 mg once every 2 weeks for induction and 
maintenance in both UC and CD43.  
Golimumab (Simponi®) is a mAb derived from transgenic mice engineered to express 
human IgG and is administered subcutaneously at a dose of 50 mg or 100 mg once 
every 4 weeks in UC and CD43.  
CZP (Cimzia®) is a monovalent Fab antibody fragment that was covalently linked to 
two cross-linked chains of polyethylene glycol to increase its half-life in vivo, 
enhance its solubility and possibly reduce its immunogenicity. Cimzia® is 
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administered via the SC route at 400 mg once every 4 weeks for induction and 
maintenance in CD16, 21,20,43.  
Due to their large size, the renal clearance of these antibodies is almost non-existent. 
The drugs’ half-life is approximately 2 weeks43. The direct comparison of these 
antibodies revealed that IFX, ADA, and CZP display comparable mTNF-α antagonist 
activity in vitro20.  
The pharmacokinetic profile of anti-TNF-α agents is influenced by many patient-, 
disease- and drug-specific factors, including body weight, immunogenicity, the use of 
concomitant immunosuppressive medication (for instance, combining the therapy 
with methotrexate delayed the decrease in the serum concentrations of IFX44) and drug 
loss through a ‘leaky gut’. These inter- and intra-individual differences contribute to 
the problem of an inadequate response and a loss of response16. In some studies, no 
anti-TNF-α was detectable in some patients 12 weeks after administration of the last 
dose44, which might explain why 12 weeks prior to the operation was selected as the 
therapeutic window in almost all studies of the effect of anti-TNF-α on postoperative 
complications45.   
1.3.3 MECHANISM OF ACTION OF ANTI-TNF-ALPHA 
The efficacy of anti-TNF-α antibodies in IBD has been attributed to several effects, 
but their precise molecular mechanisms of action have not been thoroughly 
characterized20,35. Compared with rheumatoid arthritis, a disease in which most TNF-
blocking strategies seem to be therapeutic, some mechanisms other than the 
neutralization of sTNF-α are involved in the resolution of inflammation and mucosal 
healing in CD8,20,21,46. The induction of lamina propria T cell apoptosis and reverse 
signalling, which leads to the downregulation of cytokine production and 
apoptosis,20,21 have been described as an alternative mechanism of action of anti-TNF-
α agents in vitro and in vivo.  
Apoptosis (figure 4) is a form of programmed cell death. This natural physiological 
process is essential for normal development and the maintenance of cell homeostasis. 
In contrast to necrosis, which is a form of traumatic cell death, apoptosis allows the 
‘silent’ elimination of unwanted cells. A defect in the apoptosis of T cell populations 
in the lamina propria is an important factor in the pathogenesis of IBD17,8. The use of 
endoscopy and technetium-labelled annexin V has shown that T cell apoptosis in the 
lamina propria occurs within 24 hours after the administration of IFX46. 
Bax and Bak are two nucleus-encoded proteins present in higher eukaryotes; these 
proteins can pierce the mitochondrial outer membrane and thereby mediate cell 
death by apoptosis. IFX and ADA induce apoptosis by upregulating the expression 
of Bax and Bak and thereby increasing the release of cytochrome C from the 
mitochondria into the cytosol17. Another alternative pathway leading to apoptosis is 
regulated by specific death receptors that induce the formation of a death-inducing 
signalling complex. These two pathways are illustrated in figure 4. Like all drugs, 
anti-TNF-α agents are associated with side effects, as discussed below. 
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Figure 4: Action of anti-TNF-α agents via apoptosis, which is a form of programmed cell death 
that is essential for normal development and the maintenance of cell homeostasis. A defect in the 
apoptosis of mucosal T cell populations might be important in the pathogenesis of IBD. Bax and 
Bak are two nuclear-encoded proteins that penetrate the mitochondrial outer membrane and 
mediate cell death by apoptosis. Caspase-3 is a key effector of apoptosis. FADD: Fas-associated 
death domain; tmTNF: transmembrane TNF. From Slevin 2015, Inflamm. Bowel Dis. (with 
permission from Wolters Kluwer Health, Inc.).
1.3.4 SIDE EFFECTS OF ANTI-TNF-ALPHA 
Serious infections are caused either by latent disease reactivation or by de novo 
disease acquisition. Opportunistic infections include viral infections (e.g., 
cytomegalovirus), bacterial infections (e.g., tuberculosis), and fungal infections 
(e.g., candidiasis). To prevent the development of infectious diseases during 
immunosuppressive treatment, effective vaccines should be considered prior to 
initiation of an anti-TNF-α therapy. Careful scrutiny for tuberculosis using chest X-
rays and QuantiFERON® testing is mandatory, and screening using HIV tests and 
hepatitis tests should also be performed prior to starting treatment. Potential 
malignancies (e.g., lymphoma) and paradoxical inflammation of the skin and other 
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organs, which might lead to paradoxical psoriasis and lupus-like drug reactions, 
have also been reported as serious side effects.  
 
1.3.5 SURGERY AND RISKS OF POSTOPERATIVE 
COMPLICATIONS 
For decades, surgery for CD was an option only in cases involving failed medical 
treatment. This concept was associated with a high rate of emergency surgeries, 
increased risk of short bowel syndrome, higher risk of postoperative morbidity and 
mortality and low quality of life. Fortunately, this concept has been challenged in the 
last few years, and surgery has become an option for patients with CD at various stages 
of the disease. A recent randomized controlled trial (RCT) showed that the results of 
laparoscopic ileocaecal resection with respect to quality of life are comparable to those 
of treatment with anti-TNF-α47. Rapid developments in surgery, including bowel-
sparing surgery, minimally invasive access to the abdomen, better timing of surgical 
intervention48 and better preoperative optimization49,50, have made surgery a decent 
choice for the treatment of CD. In most tertiary centres, IBD surgeons are members 
of multidisciplinary teams that are responsible for treating patients with CD. This 
collaboration might decrease the rate of emergency interventions and increase the 
chance of multi-modal preoperative optimization, thus reducing the rate of 
postoperative morbidity49.  
A recent study showed that patients need balanced information on all treatment 
options, including surgery, from a dedicated multidisciplinary team beginning at the 
early stage of their disease51. Thus, patients should meet with an IBD surgeon early in 
their treatment pathway and not just when major surgery has become inevitable. There 
are three types of surgery for CD: 
 
 
1. Stoma formation might be indicated when anastomosis is not advisable, as 
in cases of severe inflammation, intra-abdominal abscess, severe small 
bowel obstruction or large bowel ileus (megacolon). It is occasionally 
required for severe unrelenting perianal CD. Patients with CD may worry 
about stoma-forming surgery and sometimes endure a poor quality of life to 
avoid this surgery51. Early multidisciplinary counselling about stoma may 
help patients with their decision-making process. 
 
2. In strictureplasty, the affected bowel segment is incised and re-sutured 
without resection. A variety of methods have been described for 
strictureplasty (Heinke-Mikulics, Finney and Michelassi’s isoperistaltic 
side-to-side strictureplasty). Some researchers are beginning to question 
whether strictureplasty alone, rather than formal resection of the diseased 
bowel, may suffice. Recent studies have demonstrated full mucosal healing 
at the strictureplasty site52,53. These experimental ideas, if proven, might 
change the management of patients with CD, resulting in surgery being 
performed much earlier. 
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3. Resection of the affected bowel segment with primary anastomosis is the 
most frequent operation in CD51. A variety of techniques have been 
described for performing anastomosis, and these vary regarding the 
configuration (side-to-side, end-to-side, or end-to-end anastomoses), 
method (stapling or hand-sewn suture)54 and technique (extra-or intra-
corporal anastomosis). There is no overriding consensus regarding the 
optimal technique for intestinal anastomosis in CD. The choice of method 
must therefore be tailored to the individual patient. 
 
Risk of surgery 
A meta-analysis of 26 published population-based studies calculated the risks of 
surgery at 1, 5, and 10 years after a diagnosis of CD as 16.3%, 33.3%, and 46.6%, 
respectively55. However, a recent epidemiological study conducted in Europe 
showed that only 22% of patients with CD underwent resection during 5 years of 
follow-up, and 13% of these resections were performed in the first year after the 
diagnosis. The median time to first surgery was 7 months (IQR 1-30) and did not 
differ between patients in Western and Eastern Europe56. It is unclear whether the 
rate of surgery decreased or remained unchanged after the introduction of anti-TNF-
α agents57. Population-based studies have yielded conflicting results regarding the 
impact of anti-TNF-α agents on the reduction of surgical intervention in patients 
with CD58,38,59,60. The above-mentioned meta-analysis concluded that the risks of 
surgery 1, 5 and 10 years after a diagnosis of CD have decreased during the last six 
decades55. Data from referral centres’ cohorts have shown that up to 50% of patients 
are exposed to anti-TNF-α agents prior to their first surgery61,62, and this exposure 
rate has led some researchers to suspect a risk of postoperative complications in 
patients treated with anti-TNF-α agents.  
 
This suspicion is based on the knowledge that TNF-α is an important component of 
the body’s immune defence against infections in addition to being essential for wound 
healing through its effects on angiogenesis25 and collagen synthesis23,24,30. The 
inhibition of these pathways might impair wound healing after surgery and increase 
the risk of postoperative complications, such as surgical site infection and 
anastomosis-related complications, in patients with CD. This possibility has been 
investigated and debated in more than 60 studies, and the conclusions reached by the 
authors of these studies are divergent, leading to different policies regarding the 
preoperative withdrawal of anti-TNF-α. Surgery is still needed in the treatment of CD, 
but whether early surgery can alter the natural course of the disease is unclear.  
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2. OVERALL AIM AND HYPOTHESIS 
The aim of this thesis was to investigate the effect of anti-TNF-α agents on the 
postoperative outcome in patients with CD undergoing bowel resection. The 
hypothesis in question was investigated through four studies. 
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3. METHODS  
3.1 STUDY 1 
3.1.1 HYPOTHESIS AND OBJECTIVES 
Anti-TNF-α agents increase the risk of postoperative complications in patients with 
CD undergoing bowel resection. 
3.1.2 STUDY DESIGN 
The study was designed as a retrospective cohort multi-centre study using data 
collected from hospital registries. 
3.1.3 PRIMARY AND SECONDARY OUTCOME VARIABLES 
The primary outcome was intra-abdominal septic complications (IASCs) defined as 
overt anastomotic dehiscence, postoperative enteric fistula, or intra-abdominal 
abscess requiring treatment with laparotomy, laparoscopy or percutaneous 
radiologically guided drainage. The secondary outcome variables were “other 
postoperative septic complication” and “any complication.”  
3.1.4 DATA COLLECTION 
The study included operations for CD performed at four Danish university hospitals 
during the period 2000-2007. All operations involving resection and anastomosis 
and/or strictureplasty were included in the study. The diagnosis of the operated 
patients was based on operative and histopathological findings, and that of previously 
non-operated patients was based on endoscopic, radiological, and clinical findings.  
Demographic characteristics, histories of disease and of medical and surgical 
treatments, in addition the timing of the surgical intervention (acute, emergent or 
elective) were collected. A patient was considered to have had anti-TNF-α treatment 
if s/he had received IFX, ADA, CZP or golimumab within 3 months prior to the 
operation. A patient was considered to be on immunomodulation if s/he was treated 
with azathioprine, 6-mercaptopurine, or methotrexate for more than 3 months and 
received the last drug dose within 1 month prior to the operation. A patient was 
considered to be on steroids if s/he was treated for more than 4 weeks and received 
the last drug dose within 1 week before surgery. A dose of prednisolone of at least 20 
mg was considered a high dose. Operations performed within 24 hours of admission 
were considered acute, those performed within 1 week of admission were defined as 
emergent, and planned operations were defined as elective. During the postoperative 
course, any complication, readmission, and death within 30 days were registered. 
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3.1.5 STATISTICAL ANALYSIS 
Univariate comparisons were performed using Pearson’s chi-square test or Fisher’s 
exact test when appropriate. Continuous data were analysed using the Mann-Whitney 
U-test. A multivariate logistic regression analysis was employed to identify 
independent predictors of outcome. Continuous variables were dichotomized at their 
median values, and the median values were used in the binary logistic regression 
analyses. Three dependent variables were tested by the model: IASCs, septic 
complications, and “any complication”. As covariates, the model included age, 
gender, and variables that showed significant differences in the univariate analysis. A 
two-sided p value less than 0.05 was considered to indicate significance. The 
statistical analysis was performed by the first and corresponding author with help from 
a statistician (Hvidovre Hospital, research section). 
3.2 STUDY 2 
3.2.1 HYPOTHESIS AND OBJECTIVES 
Anti-TNF-α agents might increase the risk of postoperative complications due to their 
mechanism of action. It was hypothesized that pooling the data from all the published 
studies on the subject, sorting the studies according to their risk of bias and then 
analysing their results would lead to statistically powerful and clinically useful 
conclusions.  
3.2.2 STUDY DESIGN 
The study involved a systematic review and meta-analysis based on a predefined study 
protocol that was developed according to the recommendations in the Cochrane 
Handbook for Reviews of Interventions and the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement63. 
3.2.3 PRIMARY AND SECONDARY OUTCOME VARIABLES  
The primary outcome measure was anastomotic complications including overt 
anastomotic leak (dehiscence), postoperative intra-abdominal abscess or enteric 
fistula verified by diagnostic imaging, laparotomy or laparoscopy. The secondary 
outcome measures were the total numbers of complications, non-anastomotic surgical 
complications, infectious complications, major medical complications, and minor 
medical complications, reoperation, and mortality. Medical complications were 
classified as major if they were potentially life-threatening or prolonged the hospital 
stay. The remaining medical complications were classified as minor. The outcome 
measures were assessed after 30 days of follow-up. 
3.2.4 DATA COLLECTION  
Studies were identified through electronic and manual searches. The electronic 
searches were performed in MEDLINE, EMBASE, and the Cochrane Library, and all 
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databases were searched from their date of inception to September 2012. The search 
strategy for MEDLINE is included in manuscript II. 
Case control and cohort studies were included irrespective of the publication status, 
year of publication, and language. No language filter was applied; however, only 
English-language studies were found. The included studies assessed patients with CD 
undergoing laparoscopic or open abdominal surgery. To ensure the completeness of 
the evidence, studies of CD patients alone as well as studies of mixed IBD populations 
(CD and UC) were included. Based on the pharmacokinetic studies, the intervention 
group included patients who received any type or dose of anti-TNF agent within the 
3 months prior to surgery44, and patients who did not receive anti-TNF-α agents were 
included in the control group. 
One author (A.E.) performed the literature searches and listed the eligible studies. A 
research librarian at Copenhagen University library repeated the search to ensure the 
identification of all published studies.  
The excluded studies were listed, and the reasons for exclusion were reported. All the 
authors participated in the final selection of the included studies. Three authors (A.E., 
A.K., and L.G.) independently extracted the patient data, interventions, study 
characteristics and all outcome measures. Differences were resolved by discussion. 
The authors of the included studies were contacted for additional information when 
necessary. 
3.2.5 STATISTICAL ANALYSIS 
The quality of bias control in the included studies was assessed using the Newcastle-
Ottawa Scale64. Each study was assigned a number of stars based on the selection of 
patients for the intervention and control groups (maximum 4 stars), the comparability 
of the intervention and control groups (maximum 2 stars), and the ascertainment of 
the outcome of interest (maximum 3 stars). A lower number of stars indicates a greater 
risk of bias. 
The primary analyses were performed through meta-analyses using random-effects 
models due to an expected clinical heterogeneity. The results are reported as risk ratios 
(RRs) with 95% confidence intervals. Heterogeneity was assessed using the I2 statistic 
(the fraction of variance due to heterogeneity), and the resulting values classified 
(according to the Cochrane handbook with modification) the heterogeneity as 
unimportant (I2 < 30%), moderate (I2 30%-50%), substantial (I2 51%-75%), or 
considerable (I2 > 75%). Sensitivity analyses were performed by repeating the meta-
analyses on the odds ratio (OR) scale and using fixed-effects models. In addition, 
sensitivity analyses excluding the studies that included mixed populations of patients 
(CD and UC) were performed to test the influence of these studies on the results. The 
results of the sensitivity analyses are only reported if the conclusions differed from 
those reached in the primary meta-analyses. Regression analyses and the Egger test (a 
statistical test for the assessment of funnel plot asymmetry) were performed to 
evaluate the risk of small-study effects (including publication bias). Subgroup 
analyses were performed to evaluate the influence of bias control and publication 
status (full article or abstract). Differences between subgroups were evaluated using 
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the test for subgroup differences, and the results are presented as p values. An 
estimated 78 patients are needed to show a 20% difference in complications (with α 
set to 5% and power set to 80%). The analyses were performed with help from 
Liselotte Glud using RevMan version 5.0.5 (Nordic Cochrane Centre, Copenhagen, 
Denmark) and STATA (version 12, StataCorp, TX, USA). 
3.3 STUDY 3 
3.3.1 HYPOTHESIS AND OBJECTIVES 
The results of 18 retrospective studies regarding the effect of anti-TNF-α on 
postoperative outcome were conflicting, and similar findings were obtained from the 
meta-analyses based on these studies. The objective of this study was to review the 
data from the published reviews and meta-analyses to reach definitive conclusions 
concerning the impact of anti-TNF-α treatment on postoperative outcome. 
3.3.2 STUDY DESIGN  
This was a narrative systematic review. The literature search performed in this 
systematic review was the same as that used in study 2. The review was conducted 
based on a predefined study protocol that was developed according to the 
recommendations presented in the Cochrane Handbook for Reviews of Interventions 
and the PRISMA statement. 
3.3.3 PRIMARY OUTCOME VARIABLE 
The primary outcome measure was 30-day postoperative complications, with a 
particular focus on anastomotic leaks. 
3.3.4 DATA COLLECTION  
Studies were identified through electronic and manual searches. The electronic 
searches were performed in MEDLINE, EMBASE, and the Cochrane Library, and all 
databases were searched from their date of inception to September 2012. The search 
strategy for MEDLINE is described in manuscript III. 
Reviews or meta-analyses were included, and no filters were applied during the 
search. All reviews that assessed patients with CD undergoing laparoscopic or open 
abdominal surgery were included. One author (A.E.) performed the literature searches 
and listed the eligible studies. The search was then independently repeated by a 
research librarian at the University of Copenhagen Library to ensure that no relevant 
studies had been missed. All the authors participated in the final selection of the 
included studies, and differences were resolved by discussion. 
 
3.3.5 STATISTICAL ANALYSIS 
This study was a narrative systematic review without statistical analyses. The six 
meta-analyses included in the review had many methodological differences. They 
employed different inclusion criteria (for instance, inclusion of studies with mixed 
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CD and UC populations, inclusion of abstracts, inclusion of low-quality studies and 
of studies exploring only one or several anti-TNF-α agents), different outcome 
measures (for instance, anastomotic leak, overall complications or septic 
complications) and different methods for reporting outcomes (for instance, minor a 
versus major complications or medical versus surgical complications). Therefore, 
statistical analysis was not conducted in study 3. 
3.4 STUDY 4  
3.4.1 HYPOTHESIS AND OBJECTIVES 
In addition to being an important actor in immune defence, TNF-α plays a role in 
angiogenesis and collagen synthesis. Both processes are initiated by the stress 
response, and the inhibition of these pathways by anti-TNF-α agents might increase 
the risk of infections and impair wound healing in IBD patients after surgery. The aim 
of this study was to describe the surgical stress response in IBD patients and to 
investigate whether anti-TNF-α agents modify the surgical stress response and thus 
impact the postoperative outcome. 
 
3.4.2 STUDY DESIGN 
This was a prospective, non-interventional multi-centre pilot study with the following 
inclusion criteria: adult patients with CD or UC who were scheduled to undergo 
elective intestinal resection or terminal stoma closure in three Danish tertiary centres 
during the study period (March 2014-May 2016). Open and laparoscopic approaches 
were included. The exclusion criteria included patients with preoperative sepsis, 
patients with acute intestinal obstruction, patients who underwent an acute operation 
(within 48 hours of admission) and patients who underwent loop ileostomy takedown 
without laparotomy or laparoscopy. 
3.4.3 PRIMARY AND SECONDARY OUTCOME VARIABLES 
The primary outcome measure was the difference in the plasma concentrations of the 
main immunological biomarkers of the surgical stress response (TNF-α, IL-6, and IL-
10) in anti-TNF-α-treated and anti-TNF-α-naïve patients.  
The secondary outcome measures were differences in the plasma concentrations of 
other biomarkers of surgical stress, including IL-8, IL-17A, the TNF-α/IL-10 and IL-
6/IL-10 ratios, the concentration of cortisol, transferrin, ferritin, and D-dimer. in 
addition to 30-day postoperative complications as defined in the study protocol, and 
postoperative length of stay at hospital (LOS).  
Overall complications were defined as any deviation from the expected postoperative 
recovery. IASCs were defined as overt anastomotic leakages, intra-abdominal abscess 
formation or enteric fistula, and superficial surgical site infection (SSI) was defined 
as clinically documented skin infection at the site of surgery with or without positive 
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culture. The grade of the complications was assessed using the Clavien-Dindo 
classification of surgical complications. 
3.4.4 DATA COLLECTION 
Laboratory procedures 
The choice of sampling intervals of 6, 24 and 48 hours after surgical incision was 
based on previous studies11,65,66. Biomarkers of surgical stress were selected according 
to the existing evidence11,25,71–76,27,30,31,65,67–70. Peripheral blood samples were obtained 
prior to the induction of anaesthesia and 6, 24 and 48 hours after surgical incision. 
EDTA-treated plasma and serum were separated by centrifugation, aliquoted and 
stored at -80°C until analysis.  
The concentrations of anti-TNF-α agents in peripheral blood (drug concentration) and 
of antibodies against the specific compound used in the treatment (anti-drug 
antibodies) were measured on the day of surgery. The details of the methods used are 
explained on the laboratory homepage77. 
Cortisol was measured by ELISA (catalogue number EIA 1887, DRG International, 
Inc., Marburg, Germany). IL-6, IL-10, IL-17A, and TNF-α were measured using a 
human high-sensitivity magnetic ProCartaPlex Luminex kit (catalogue number 
EPX040-00000-801, eBioscience, Vienna, Austria). IL-8 and D-dimer were measured 
using ProCartaPlex Human IL-8 Simplex, ProCartaPlex Human D-Dimer Simplex, 
and Human Basic kits (catalogue numbers EPX010-10204-901, EPX010-12149-901, 
and EPX010-10420-901, eBioscience, Vienna, Austria). All samples were measured 
in duplicate according to the manufacturer’s instructions, and the means of the 
obtained values were used in the statistical analyses. The plasma levels of CRP, 
transferrin, ferritin and D-dimer were measured by the Department of Clinical 
Biochemistry of Copenhagen University Hospital, Amager and Hvidovre, Denmark, 
using standard methods. 
 
Anaesthesia, surgery and postoperative care 
The incision time in all the included operations was approximately between 08:00 
a.m. and 12:00 p.m. to eliminate/minimize circadian rhythm variation as a 
confounder. General anaesthesia was administered according to the standard practice 
of the anaesthesia department in the participating hospitals with modifications 
according to the study protocol. These modifications included the avoidance of 
steroids, NSAIDs and epidural analgesia. All patients received a single dose of 
prophylactic preoperative antibiotics at the induction of anaesthesia. The type and 
dose of anaesthesia were determined by the local standard of preoperative care in the 
participating hospitals. Laparoscopic surgery and enhanced postoperative recovery 
principles were the standard procedures in the participating centres. 
Ethical considerations 
The study was approved by the Ethics Committee in the capital region (reference 
number H-2-2013-166) and the region of Zealand (SJ-399) and by the Danish Data 
Protection Agency (Datatilsynet) in the capital region (reference number HVH-2013-
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046 / 02515) and the region of Zealand (reference number REG-85-2013). The study 
was registered at clinicaltrials.gov (Identifier: NCT01974869) and Trial map on the 
ESCP website (http://www.escp.eu.com/research/international-trials/trials-map). 
This study adhered to the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines. 
3.4.5 STATISTICAL ANALYSES 
Sample size 
The reference values for the changes in biomarkers for surgical stress in IBD patients 
that were needed for precise sample size calculation were not available at the time of 
the study. Chalhoub et al. showed that 28 patients were needed to demonstrate a 
significant change in TNF-α concentration after moderately stressful surgery78. 
Dimopoulou et al.69 detected a significant correlation between TNF-α concentration 
and postoperative complications using 40 patients. Both of the foregoing studies were 
conducted on non-IBD patients but used settings similar to those used in study 4. 
Based on these two studies and on a meta-analyses by the authors79, the study was a 
priori designed to recruit at least 40 patients, 1/3 of whom had received anti-TNF-α 
treatment prior to surgery.  
 
Statistical methods 
The preoperative and perioperative characteristics of the anti-TNF-α-treated and anti-
TNF-α-naive patients were compared using the chi-squared test. Median, interquartile 
range (IQR), and minimum and maximum values were used to compare the changes 
in the concentration of biomarkers from baseline (before operation) to each of the 
postoperative follow-up time points (6, 24 and 48 hours after surgical incision). The 
differences in the median values of the changes from baseline in the anti-TNF-α-
treated and anti-TNF-α-naive patients were assessed using a bootstrap approach. To 
reduce bias from confounding factors, the calculated medians were weighted using a 
propensity score, i.e., the inverse of the estimated probability of the administered anti-
TNF-α regimen conditional on potential confounders. These probabilities were 
estimated using a multivariable logistic regression model that included the Harvey-
Bradshaw index of disease severity, a nutritional risk screening score, whether 
parenteral nutrition was used, previous IBD-related abdominal operations, steroid 
stress dose (high dose of steroids with induction of anaesthesia in patients who 
received this treatment or who received steroids in the preoperative period), 
preoperative dexamethasone, epidural analgesia, method of access to the abdominal 
cavity (open versus laparoscopic), type of resection and disease classification in cases 
of CD. These factors were either significantly different among the patients who 
underwent the two anti-TNF-α regimens or were deemed to be important determinants 
based on clinical experience. Propensity scores were recalculated within each 
bootstrap replicate.  
Logistic regression was used to investigate the postoperative outcome, and adjustment 
for confounding factors was performed by stepwise backwards elimination beginning 
with a model that included all pre- and perioperative characteristics that were deemed 
 
 
39 
 
to be clinically and/or statistically significantly different between the two treatment 
groups. The variables were then removed one by one until all variables had a p value 
< 0.10. 
All analyses except the bootstrap analyses were performed using IBM SPSS Statistics 
for Windows, Version 19.0, IBM Corp. 2010 (Armonk, NY, USA). The bootstrap 
analyses were performed in the R environment for statistical computing version 3.1.2. 
A significance level of 5% was chosen.   
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4. RESULTS
4.1.1 RESULTS OF STUDY 1 
The study included 417 operations on 369 patients (249 women); the median age at 
operation was 37 years (range 8-90 years). Thirty-two patients received preoperative 
anti-TNF-α treatment. There were no differences in the demographics or 
preoperative characteristics of the patients between the two groups (Table 1).  
IASCs occurred in 13% (52/417) of the operations. Of these complications, overt 
anastomotic leak occurred in 7% (29/417), postoperative intra-abdominal abscess 
occurred in 9% (36/417), and postoperative enteric fistula occurred in 1% (3/417). 
Other septic complications occurred in 22% (93/417) of the operations. At least one 
postoperative complication occurred in 34% (141/417) of the operations, and re-
intervention within 30 days was needed in 16% (65/417) of the cases. Five patients 
died, four of them due to sequelae of anastomotic leaks. The median postoperative 
stay was 7 days (2-157). 
Table 1: Background data for 32 patients treated preoperatively with anti-TNF-α agents and 385 
patients without anti-TNF-α treatment. 
Anti-TNF-α 
n = 32 
No anti-TNF-α n = 
385 
Age (mean and range in years) 33 (18-62) 37 (8-90) 
Gender (female) 34.4% (11/32) 59.2% (228/385) 
Duration of disease (mean and range 
in months) 
84 (4-337) 50 (0-444) 
Previous CD laparotomy/ laparoscopy 40.6% (13/32) 42.9% (165/385) 
Operation urgency 
   Acute 25% (8/32) 23.1% (89/385) 
   Emergent or elective 75 % (24/32) 76.9% (296/385) 
Steroids preoperatively 34.4 % (11/32) 34.5 % (135/385) 
Steroids, 20 mg or more prednisolone 
preoperatively   
15.6% (5/32) 15.8% (61/385) 
Preoperative immunomodulation 87.5% (28/32) 35.8% (135/385) 
Preoperative fistula or abscess 34.4% (11/32) 19.2% (74/32) 
The values are the medians (ranges) or percentages (numbers). 
No differences in the rates of IASCs, septic complications, or any other complications 
were found between patients with and those without preoperative anti-TNF-α 
treatment (Table 2). Similarly, no differences in complication rates were found 
between patients on immunomodulation and those who were treated with a 
combination of preoperative anti-TNF-α and immunomodulation. Treatment with a 
prednisolone dose of at least 20 mg or more increased IASCs from 11% to 19% 
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(p=0.04) but was associated with no difference in the rate of septic complications or 
any complications. In multivariate analyses, treatment with prednisolone 20 mg or 
more, operation time and colocolic anastomoses were independent predictors of 
IASCs. Perioperative bleeding was an independent predictor of postoperative septic 
complications; age, intraoperative bleeding, and duration of operation were predictors 
for any complication. 
Table 2 Potential risk factors for postoperative intra-abdominal septic complications (IASCs) in 417 
abdominal operations for Crohn’s disease with anastomosis and/or strictureplasty. 
Operations 
n (%) 
Complics. 
n (%) 
Univ. 
p 
Odds ratio 
(95% CI) 
Log 
reg 
p 
Sex   Female 
 Male 
249 (59.7%) 
168 (40.3%) 
34 (13.6%) 
19 (10.7%) 
0.373 1.379 (0.703-2.704) 0.3
5 
Age        < 37 years 
≥ 37 years 
208 (49.9%) 
209 (50.1%) 
36 (17.3%) 
16 (7.7%) 
0.003 1.020 (0.999-1.042) 0.063 
Dis. duration 
< 55 months 
≥ 55 months 
209 (50.1%) 
208 (49.9%) 
33 (15.8%) 
19 (9.1%) 
0.040 0.604 (0.291-1.256) 0.177 
Previous CD 
resections 
No 
Yes 
239 (%) 
178 (%) 
25 (10.5%) 
27 (15.2%) 
0.150 0.828 (0.407-1.684) 0.602 
Priority of 
surgery 
Elective/emergent 
Acute 
320 (76.7%) 
97 (23.3%) 
40 (12.5%) 
12 (12.4%) 
0.97 0.834 (0.390-
1.784) 
0.640 
Preoperative 
fistula/abscess 
No 
Yes 
332 (79.6%) 
85 (20.4%) 
12 (14.1%) 
40 (12%) 
0.606 0.929 (0.431-1.999) 0.850 
Steroids 
> 20 mg
No
Yes
351 (84.2%) 
66 (15.8%) 
39 (11.1%) 
13 (19.7%) 
0.040 0.355 (0.167-0.756) 0.007 
Immunomoduln. 
No 
Yes 
251 (60.2%) 
166 (39.8%) 
35 (13.9%) 
17 (10.2%) 
0.263 1.230 (0.613-2.469) 0.560 
Anti-TNF-α 
treatment 
No 
Yes 
385 (92.3%) 
32 (7.7%) 
49 (12.7%) 
3 (9.4%) 
0.581 1.243(0.314-4.928) 0.757 
Table 2 is continued on the next page 
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Table 2 continued 
Operations 
n (%) 
Complics. 
n (%) 
Univ. 
p 
Odds ratio 
(95% CI) 
Log. 
reg p 
Immunomoduln. 
& anti-TNF-αal  
Neither 
Both 
251 (92.3%) 
32 (7.7%) 
50 (13%) 
2 (6.3%) 
0.268 2.044 (0.465-8.993) 0.344 
Colocolic 
anastomosis 
No 
Yes 
402 (96.4%) 
15 (3.6%) 
47 (11.7%) 
5 (33.3%) 
0.013 0.197 (0.058-0.667) 0.009 
No. of anastomoses 
or strictureplasties 
1 
> 1
384 (92.1%) 
33 (7.9%) 
45 (11.7%) 
7 (21.2%) 
0.113 0.456 (0.159-1.305) 0.143 
Anastomosis 
technique 
Hand-sewn 
Stapled 
Missing 
254 (60.9%) 
140 (33.6%) 
23 
27 (10.6%) 
22 (15.7%) 
0.156 1.130 (0.395-3.234) 0.820 
Duration of 
operation 
< 118 min 
≥ 118 min 
200 (47.96%) 
217 (52.04%) 
33 (16.4%) 
19 (8.8%) 
0.018 1.010 (1.005-1.015) < 0.01 
Periop. bleeding 
< 150 ml 
≥ 150 ml  
212 (50.8%) 
205 (49.2%) 
23 (10.8%) 
29 (14.1%) 
0.0291 0.991 (0.499-1.966) 0.979 
Complics.: complications; immunomoduln.: immunomodulators; preop: preoperative; periop.: peri-
operative, univ.: univariate analyses; log. reg.: logistic regression analyses.  
4.1.2 LIMITATIONS OF STUDY 1 
The design of study 1 was retrospective, with all the inherent limitations of this type 
of design. Follow-up was limited to 30 postoperative days. Selection bias (patients 
who receive anti-TNF-α are generally those with severe disease), differences in 
reporting outcomes due to lack of a predefined protocol at the time of the event, and 
lack of registration of other possible confounding factors, such as disease severity, 
nutritional status and the anti-TNF-α treatment details, are among the most important 
limitations of this and other retrospective studies that have investigated this issue. The 
combination of anastomoses and strictureplasty might have diluted the rate of 
anastomotic leaks. 
4.2.1 RESULTS OF STUDY 2 
In total, 14 studies (figure 5) fulfilled the inclusion criteria80,81,90–93,82–89; of these 
studies, two studies had only been published as abstracts86,92 at the time of writing. 
One of these abstracts was recently published as an original research article94. The 
author of the other abstract 86 was contacted to ascertain the fate of the study, but no 
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answer was received. The studies included 697 patients in the intervention (anti-TNF-
α agents) group and 2345 patients in the control group. Eleven studies included 
patients with CD, and three included patients with CD, UC, or indeterminate 
colitis82,89,91. These three mixed-population studies included 776 patients, of whom 
183 received anti-TNF-α treatment. The patients in the intervention group received 
their last dose of the anti-TNF-α agent 4 to 12 weeks prior to surgery.  
     Figure 5: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) diagram implemented in study 2. The diagram shows the results of the 
search and the reasons for the selection of the 14 studies that were included in the 
meta-analysis. 
All studies were retrospective (figure 5). The selection of patients was classified as 
adequate in all studies. Bias in the outcome assessment was detected in two studies. 
Three studies85,86,87 did not adjust for potential confounding factors in an adequate 
manner. Based on the quality assessment, three studies were classified as having a 
high risk of bias (≤ 6 stars), seven studies were classified as having a medium risk of 
bias (7 stars), and four were classified as having a low risk of bias (8 stars).   
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Table 3: Characteristics of the studies included in the meta-analysis (study 2). Twelve original studies 
and two abstracts were included in the meta-analysis. One of the included abstracts was published as 
an original study (Kotz et al.); the other abstract (Brzezinski et al.) was not published. The Newcastle-
Ottawa Quality Assessment Scale for Cohort Studies is a tool that facilitates quality control in 
observational studies. A study can be awarded a maximum of one star for each numbered item within 
the Selection and Outcome categories, and a maximum of two stars can be given for comparability. 
Author Quality assessment 
(Newcastle-Ottawa 
Scale) 
Type of 
anti- 
TNF- 
agent 
Number of patients treated 
with anti-TNF- agents 
with/without other 
medications 
Number of 
untreated 
patients 
(control) 
Brzezinski et 
al. 86 2002 
Selection: *** 
Comparison: * 
Outcome: **     
IFX Total: 22 (CD n = 16) 
+ST: NR
+IM: NR 
Total: 41 
+ST: NR
+IM: NR 
Tay et al. 90
2003 
Selection: ***     
Comparison: *   
Outcome: ***        
IFX Total: 22 
+ST: NR
+IM: 20
Total: 78 
+ST: 14
+IM: 70
No therapy: 7
Colombel et 
al. 85 2004 
Selection:***      
Comparison: * 
Outcome: **    
IFX Total: 52 
+ST: 19
+IM: 19
+ST & IM: 53
Total: 218 
+ST: 34
+IM: 8
+ST & IM: 6
No therapy: 33
Marchal et 
al. 83 2004 
Selection: *** 
Comparison: *   
Outcome: **   
IFX Total: 40 
+ST: 12
+IM: 24
+ST & IM: 29
Other: 22
Total: 39 
+ST: 12
+IM: 11
+ST & IM: 16
Other: 32
Appau et al. 
81 2008 
Selection: *** 
Comparison: ** 
Outcome: *** 
IFX Total: 60 
+ST: 39
+IM: 37
Other: 36
Total: 329 (69) 
+ST: 253
+IM: 55
Other: 196
Kunitake et 
al. 82 2008 
Selection: ***     
Comparison: ** 
Outcome: *** 
IFX Total: 101 (CD n = 57) 
+ST: 76
+IM: 37
Total: 312 (CD n 
= 131) 
+ST: 240
+IM: 81
Indar et al. 87 
2009 
Selection: ***    
Comparison: * 
Outcome: * 
IFX Total: 17 
+ST: 7
+IM: 5
+St & +IM: 3
Total: 95 
+ST: 21
+IM: 15
+St & +IM: 16
No treatment: 43
Regadas et 
al. 89 2010 
Selection: *** 
Comparison:* 
Outcome: ***     
IFX Total: 28 (CD n = 7) 
+ST: 14
+IM: 11
+ST & IM: 4
Total: 221 
+ST: 72 (CD n =
5) 
+ST & IM: 35
(CD n = 2) 
No treatment:
114 (CD n = 7) 
Nasir et al. 84
2010 
Selection: ***    
Comparison: ** 
Outcome: ***     
IFX, 
ADA, 
CZP 
Total: 119 
+ST: 37
+IM: 32
Total: 251 
+ST: 114
+IM: 83
Kasparek et 
al. 88 2011 
Selection: *** 
Comparison: * 
Outcome: ***    
IFX Total: 48 
+ST: 45
+IM: 35
Total: 48 
+ST: 45
+IM: 35
Table 3 is continued on the next page 
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Table 3 continued 
Author Quality assessment 
(Newcastle-Ottawa 
Scale) 
Type of 
anti- 
TNF- 
agent 
Number of patients treated 
with anti-TNF- agents 
with/without other 
medications 
Number of 
untreated 
patients 
(control) 
Canedo et 
al. 93 2011 
Selection: ***   
Comparison: ** 
Outcome: ***    
IFX Total: 65 
ST and/or IM: NR 
Total: 160 
ST and/or IM: 85 
Other: 75 
Rizzo et al. 91
2011 
Selection: ***    
Comparison: * 
Outcome: ***    
IFX, ADA 
CZP 
Total: 54 (CD n = 37) 
+ST: 19 (CD n = 10) 
+IM:21 (CD n = 18) 
+ST & IM: 7 (CD n = 5) 
Other: 11
Total: 60 (CD n 
= 38) 
+ST: 29 (CD n =
?)
+IM: 6 (CD n =
?)
Other: 14
Kotz et al. 92
2011 
Selection: ***    
Comparison: * 
Outcome:***     
IFX and 
ADA 
Total: 19 
+ST: NR
+IM: NR 
Total: 57 
+ST: NR
+IM: NR 
El-Hussuna 
et al. 80 2012 
Selection: ***     
Comparison: * 
Outcome: ***     
IFX and 
CZP 
Total: 32 
+ST: 21
+IM: 28
Total: 385 
+ST: 75
+IM: 79
+ST&IM: 58 
No treatment:
171 
CD: Crohn’s disease; NR: not reported in the study; +ST: treated with steroids; +IM: treated with 
immunomodulators. Only patients who received preoperative anti-TNF-α agents are reported; patients 
who received anti-TNF-α agents after surgery are not reported, as in, for instance, the abstract published 
by Brezezinski et al. 
Effect of anti-TNF agents on anastomotic complications 
Eleven studies80,81,93,82–84,88–92 reported anastomotic complications, which were 
diagnosed in 45 of 593 patients (7.6%) in the anti-TNF-α group and 143 of 1747 
controls (8.2%). Random-effects meta-analyses found no difference between the anti-
TNF-α and control groups (RR, 0.91; 95% CI, 0.56-1.47; figure 6). There was 
moderate heterogeneity (I2 = 44.5%). The results were stable in sensitivity analyses 
using the OR scale (OR, 0.90; 95% CI, 0.53-1.53), the fixed effects meta-analysis 
(RR, 0.97; 95% CI, 0.70-1.33), and after exclusion of the trials with mixed patient 
populations (RR, 1.06; 95% CI, 0.41-2.74). Regression analyses showed evidence of 
small-study effects (Egger test p = 0.027 (that is, smaller studies might show 
different, often larger, treatment effects than larger ones). Subgroup analyses found 
a significant difference between groups of studies stratified by the risk of bias (test for 
subgroup differences p = 0.004). The studies with a low risk of bias found that anti-
TNF-α agents increased the risk of anastomotic complications (RR, 1.63; 95% CI, 
1.03-2.60; number needed to harm, 37 patients), but this association was not found 
in the studies with a medium bias risk (RR, 0.17; 95% CI, 0.05-0.60). Figure 6 
illustrates these findings. It was not possible to extract data on 
anastomotic complications from the studies with a high risk of bias.  
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Secondary outcomes  
Thirteen studies80,81,91,82–89 reported the total number of patients with complications 
(Tay et al. reported only IASCs90). The fixed-effects meta-analysis revealed that 
treatment with anti-TNF-α agents increased the total number of complications (238 of 
419 patients (56.8%) versus 589 of 1627 patients (36.2%); RR, 1.25; 95% CI, 1.10-
1.43; I2 = 81.8%), but no such effect was observed in the random-effects meta-analysis 
(RR, 1.18; 95% CI, 0.86-1.62). There were no small-study effects (Egger test p = 
0.459). Subgroup analysis showed a difference between studies stratified by the risk 
of bias (test for subgroup differences p < 0.001). The studies with a high risk of bias 
found no difference between the anti-TNF-α and control groups (RR, 0.79; 95% CI, 
0.58-1.08). Treatment with anti-TNF-α agents increased the total number of patients 
with complications in studies with a medium or low risk of bias (RR, 1.28; 95% CI, 
1.04-1.56 and RR, 1.77; 95% CI, 1.46-2.15). Mortality was reported in 12 studies, and 
no events were reported in seven studies. In the remaining five studies (all classified 
as having a low risk of bias), 10 of 231 patients in the anti-TNF-α group (4.3%) and 
10 of 792 patients in the control group (1.3%) died. The intervention increased the 
mortality rate in the fixed-effects meta-analyses (RR, 7.01; 95% CI, 2.75-17.84) but 
not in the random-effects meta-analysis (RR, 4.80; 95% CI, 0.66-34.82). There was 
substantial heterogeneity (I2 = 53.4%) and no evidence of small-study effects (Egger 
test p = 0.627). 
Nine studies80–84,88,89,91,93 reported other (non-anastomotic) surgical complications, 
including wound infections, prolonged ileus, adhesions, bleeding gastric ulcers, and 
wound dehiscence. In total, 74 of 473 patients in the anti-TNF-α group (15.6%) and 
180 of 1625 controls (1.1%) experienced other surgical complications (RR, 1.40; 95% 
CI, 1.05-1.85; I2 = 0%; Egger test p = 0.545). Major medical complications, including 
acute renal failure and thromboembolic and cardiovascular complications, were 
registered in 24 of 458 (4.4%) patients in the anti-TNF-α group and 51 of 1594 
patients (3.2%) in the control group. Anti-TNF-α treatment increased the risk of major 
medical complications (RR, 1.97; 95% CI, 1.23-3.14). There was no heterogeneity 
and no small-study effect (I2 = 0% and Egger test p = 0.083). Forty-nine of 369 
patients in the anti-TNF-α group (13.3%) and 41 of 1156 controls (3.5%) developed 
minor medical complications (RR, 2.37; 95% CI, 1.24-4.50; I2 = 37.4%; Egger test p 
= 0.262). The risk of infectious complications did not differ between the anti-TNF-α 
and control groups (93 of 359 patients (25.9%) versus 261 of 1290 patients (20.2%); 
RR, 1.15; 95% CI, 0.86-1.53; I2 = 33.8%; Egger test p = 0.834). Reoperation was 
reported in five studies and occurred in 21 of 212 patients (9.9%) in the anti-TNF-α 
group versus 89 of 1106 patients (8.05%) in the control group (RR, 1.09; 95% CI, 
0.61-1.95; I2 = 19.6%; Egger test p = 0.577). 
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    Figure 6: Meta-analysis of observational studies of postoperative anastomotic 
complications in patients with Crohn’s disease. The studies are stratified according to 
the risk of bias, as assessed using the Newcastle-Ottawa Scale. In the studies with the 
lowest risk of bias, anti-TNF-α agents increased the risk of anastomotic complications 
(RR, 1.63; 95% CI, 1.03-2.60), but this increase was not detected in the studies with a 
medium risk of bias (RR, 0.17; 95% CI, 0.05-0.60). RR = risk ratio. 
4.2.2 LIMITATIONS OF STUDY 2 
The main limitation of this review is related to the design of the included studies. The 
observational design entails a risk of bias that cannot be eliminated through adjusted 
analyses. Moreover, many potential confounding factors were not addressed in all the 
included studies. 
4.3.1 RESULTS OF STUDY 3 
As of 4 July 2013, there were 18 retrospective studies on the effect of anti-TNF-α 
treatment on postoperative complications in CD patients undergoing abdominal 
surgery80,81,92,93,95–98,82,83,85–88,90,91. These studies have been the subject of two 
systematic reviews99,100 and six meta-analyses79,101–105. The PRISMA diagram is 
shown in figure 7. 
The first narrative review by Subramanian et al. was limited to three studies that 
included 425 CD patients, of whom 108 were preoperatively treated. The authors 
concluded that the available evidence does not suggest an increased rate of 
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postoperative complications after preoperative treatment. Ali et al.100 reviewed eight 
studies: three on CD patients, four on UC patients, and one with a mixed IBD 
population. In total, these studies included 1,372 CD patients, of whom 199 were 
treated with anti-TNF-α. The authors claimed that it was not possible to reach definite 
conclusions because “the studies are limited by small numbers of patients, disparate 
comparison groups, different definitions of measured outcomes and varying 
timeframes of drug exposure and follow-up”. 
    Figure 7: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) diagram implemented in study 3. The figure shows the process used to 
select the eight studies included in the review. 
The major findings of the six meta-analyses are presented in Table 4. The first 
analysis, which was conducted by Efthasami et al.103, focused on colectomy rates and 
postoperative complications in UC and CD patients. The method used for quality 
assessment in this study was basically designed for randomized controlled clinical 
trials. No sensitivity analysis was conducted to identify studies with a high risk of 
bias. This study had many crucial drawbacks, including the mixing of retrospective 
and randomized studies, the mixing of studies on the recurrence of disease with those 
that examined postoperative complications, and the reporting of results in a non-
systematic manner. The study results were difficult to interpret. This study revealed 
an increased risk for overt anastomotic leaks, pouch-related complications, infections 
and thrombotic events after anti-TNF-α treatment. Not all relevant studies were 
included. No subgroup analysis of CD patients was performed, and the results are not 
applicable to these patients. 
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Table 4: Meta-analyses of the relationship between anti-TNF-α treatment and postoperative 
complications in Crohn’s disease. A statistical comparison could not be performed due to the use of 
different inclusion criteria and wide variations in the reporting of the outcome measures. 
Study Disease 
studied 
No. 
of 
studs. 
Medication Treated/ 
Total No. 
of CD 
patients 
Method of 
quality 
assessment 
Results after 
application of quality 
assessment. a
Ehteshami-
Afshar et 
al. 103 2011 
CD & 
UC 
3 CD, 
8 UC 
& 
1 
mixed 
IFX 253/1,151 Jadad All: 
OR = 2.11 (CI: 1.02-4.36) 
Anastomotic: 
OR = 1.71 (CI: 1.02-2.87) 
Infectious: 
OR = 1.56 (CI: 0.71-
3.44)a 
Kopylov et 
al. 101 2012 
CD 8 Anti-TNF-
α agents 
423/1,641 NOS  
(excluded 
studies were 
not 
mentioned) 
All: 
OR = 2.2 (CI: 0.96-5.04) 
Anastomotic: 
OR = 1.18 (CI: 0.61-2.30) 
Infectious: 
OR = 1.62 (CI: 0.92-2.86) 
Rosenfeld 
et al. 104
2013 
CD 6 IFX 257/1,159 - Major: 
OR = 1.59 (CI: 0.89-2.86) 
Minor: 
OR = 1.8 (CI: 0.87-3.71) 
Billioud et 
al. 102 2013 
CD, 
UC & 
IC 
9 CD, 
9 UC 
& 
3 
mixed 
Anti-TNF- 
α agents 
977/4,251 
(pure CD 
patients 
549/1,907) 
- All: 
OR = 1.31 (CI: 0.96-1.77) 
Anastomotic: 
Not stated 
Infectious: 
OR = 1.45 (CI: 1.03-2.05) 
Narula et 
al. 105 2013 
CD & 
UC 
7 CD, 
8 UC 
& 
3 
mixed 
1,146/4,659 NOS All: 
OR = 2.19 (CI: 1.69-2.84) 
Anastomotic: 
Not stated 
Infectious: 
OR = 1.93 (CI: 1.28-
2.89)b
El-
Hussuna et 
al. 79 2013 
CD 11 
CD & 
3 
mixed 
Anti-TNF-
α agents 
679/3,042 NOS All: 
RR = 1.77 (CI: 1.46-2.15) 
Anastomotic: 
RR = 1.63 (CI: 1.03-2.60) 
Infectious: 
RR = 1.15 (CI: 0.86-1.53) 
CD = Crohn’s disease; IC = indeterminate colitis; NOS = Newcastle-Ottawa Scale; UC = ulcerative colitis; 
No.: number. 
a. The results are expressed as overall complications (All), anastomosis-related complications
(Anastomotic) and infectious complications (Infectious).
b. Complications are presented for both CD and UC.
The two meta-analyses from 2012 and 2013 included more than 1,000 patients each. 
Kopylov et al.101 addressed many of the limitations of the previous reviews in their 
meta-analysis. However, these authors excluded abstracts and three relevant studies 
of mixed populations of patients with CD, UC and indeterminate colitis and did not 
report the results obtained after the application of quality assessment. Nevertheless, 
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these researchers reported an increase in infectious complications in addition to trends 
of increased overall and non-infectious complications. No increase in the risk of 
anastomotic complications was detected in a subgroup analysis, and the authors noted 
that the statistical analysis was influenced by discrepancies in the classification of 
complications. 
Rosenfeld et al.104 found no difference in the rates of major complications, minor 
complications, re-operation or 30-day mortality between the IFX and control groups. 
Sensitivity analyses performed by excluding individual studies had no influence on 
the results. The review excluded some studies that reported the use of anti-TNF-α 
agents other than IFX. Moreover, it also included abstracts in the results section but 
excluded them from the analysis, which might be confusing. No quality assessment 
was reported, and the results obtained after the complications were grouped into major 
and minor complications were not comparable with those of other meta-analyses. In 
addition to the above-mentioned drawbacks, the authors admit that the small number 
of included studies indicates a low power to detect bias. 
Three recent meta-analyses included more than 3,000 operations. Billioud et al.102 
examined several studies of CD and UC patients but did not apply any quality 
assessment or sensitivity analysis. These researchers found an increased risk of 
infectious complications in CD patients. There was no subgroup analysis of 
anastomotic complications. Narula et al.105 performed a meticulous sensitivity 
analysis and applied a quality assessment by excluding studies with a high risk of bias. 
These researchers found that treatment with anti-TNF-α agents was associated with 
increased risks of overall and infectious complications and revealed a trend towards 
an increase in non-infectious complications. These authors did not analyse 
anastomosis-related complications, although they included 7 studies that reported 
anastomotic leak in CD81–84,88,91,93. The most recent meta-analysis by El-Hussuna et 
al.79 applied quality assessment and sensitivity analysis, excluding studies with mixed 
populations. After excluding studies with a high risk of bias, the authors found 
increases in the risks of overall postoperative complications and anastomosis-related 
complications in patients treated with anti-TNF-α. 
4.3.2 LIMITATIONS 
Although this study was cited and used as a reference study in an ESCP-ECCO 2016 
statement on anti-TNF-α and postoperative outcome106, it has some limitations, one 
of which is that it is a narrative review. The included meta-analyses used different 
outcome definitions and different inclusion criteria and implemented bias control to 
varying degrees. 
4.4.1 RESULTS OF STUDY 4 
This pilot study succeeded in recruiting 46 patients, of whom 18 had been treated with 
an anti-TNF-α agent within 3 months prior to surgery (Table 5).   
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Table 5: Preoperative and intraoperative characteristics of 46 IBD patients treated with anti-
TNF-α compared with those of anti-TNF-α-naïve patients. 
Patient characteristics Anti-TNF-α 
treated  
18/46 (39.1%) 
Anti-TNF-α 
naïve 
28/46 (60.9%) 
Uni- 
variate 
Age in years (mean ± SD) 38.7 ± 16.36 44.39 ± 12.62 ns 
Female 11/18 (61.1%) 14/28 (50%) ns 
Body mass index (kg/m2) 24.93 (± SD 
6.12) 
24.7 (± SD 
5.37) 
ns 
Type of disease n (%): Crohn’s disease 
     Ulcerative colitis 
13/18 (72.2%) 
5/18 (27.8%) 
19/28 (67.9%) 
9/28 (32.1%) 
ns 
Smoking n (%):           Non-smoker or ex-smoker    
    Smoker 
14/18 (77.8%) 
4/18 (22.2%) 
22/28 (78.6%) 
6/28 (21.4%) ns 
Steroids n (%): 
Immunomodulators n (%): 
7/18 (38.9%) 
8/18 (44.4%) 
9/28 (32.1%) 
7/28 (25%) ns 
NSAID intake preoperative n (%): 0 1/28 (3.6%) ns 
Anti-coagulant intake n (%): 1/18 (5.6%) 0 ns 
Harvey-Bradshaw Index in CD patients above the 
calculated median (7.5) n (%): 
4/18 (36.4%) 8/28 (61.5%) ns 
Preoperative albumin mmol/l 
(mean ± SD)  
33.22 ± 7.53 36.89 ± 4.36 ns 
Preoperative haemoglobin mmol/l 
(mean ± SD) 
7.86 ± 0.94 8.09 ± 1.01 ns 
Nutritional risk screening score n (%): No risk 
Mild 
Moderate 
Severe 
6/18 (33.3%) 
6/18 (33.3%) 
3/18 (16.75) 
3/18 (16.7%) 
20/28 (71.4%) 
4/28 (14.3%) 
2/28 (7.1%) 
2/28 (7.1%) 
ns 
Preoperative parenteral nutrition n (%): 5/18 (27.8%) 1/28 (3.6%) p = 0.028 
Steroid stress dose n (%): 5/18 (27.8%) 0 p = 0.003 
Dexamethasone n (%): 4 mg 
     8 mg 
1/18 (5.6%) 
2/18 (11.1) 
1/28 (3.6%) 
9/28 (32.1%) ns 
Preoperative epidural analgesia n (%): 5/18 (27.8%) 7/28 (25%) ns 
Access to abdomen n (%): Laparoscopic 
 Converted 
 Open 
13/18 (72.2%) 
3/18 (16.7%) 
2/18 (11.1%) 
17/28 (60.7%) 
2/28 (7.1%) 
9/28 (32.15%) 
ns 
Type or resection n (%):   SM & IC 
 Colectomy and/or rectal 
 stoma closure 
9/18 (50%) 
8/18 (44.4%) 
1/18 (5.5%) 
11/28 (39.3%) 
12/28 (42.9%) 
5/28 (17.8%) 
ns 
Postoperative epidural analgesia n (%): 6/18 (33.3%) 12/28 (42.9%) ns 
Postoperative NSAID used n (%): 0 2/28 (7.1%) ns 
Postoperative parenteral nutritional support n (%): 5/18 (27.8%) 1/28 (3.6%) p = 0.028 
All operations were performed with a specialist surgeon in charge. Anti-TNF-α: anti-tumour necrosis factor 
drugs; ns: non-significant; SM: small bowel; IC: ileocolic.
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Background characteristics 
The median age was 42.5 years (IQR 23 years), and 25 of 46 patients were female 
(54.3%). Four of the 18 (22.2%) patients in the anti-TNF-α-treated group had one or 
more comorbidities compared with 7 of 28 (31.8%) patients in the anti-TNF-α-naïve 
group. The duration of disease in the anti-TNF-α-treated patients (median 5 years, 
IQR 7 years) and anti-TNF-α-naive patients (median 8.5 years, IQR 12 years) did not 
differ. The pre-and intraoperative characteristics of the patients are reported in Table 
5. 
The anti-TNF-α-naïve patients had a higher rate of previous IBD surgeries compared 
with the anti-TNF-α-treated patients (p = 0.003). The anti-TNF-α-treated patients 
were more likely to have received preoperative parenteral nutritional support (p = 
0.028). Moreover, anti-TNF-α-treated patients with CD had a greater mean 
ileocaecal/ileocolic resected segment length (mean 31.11 ± 35.51 (SD) cm) versus 
27.43 ± 18.83 (SD) cm, respectively; p = 0.036) and were more likely to have a 
stricturing CD phenotype (10/76.9% versus 8/42.1%, respectively; p = 0.01) 
compared with the anti-TNF-α-naïve patients. The type of surgical incision and the 
type of bowel resection were similar in the two groups. 
The 18 patients who received anti-TNF-α preoperatively were treated with different 
types of anti-TNF-α drugs at different doses, and there were wide variations in the 
interval between the last administered dose and surgery (Table 6). Thus, 44% of the 
anti-TNF-α-treated patients had undetectable drug concentrations in their peripheral 
blood, and only three of these 18 patients had anti-drug antibodies at the time of 
surgery.  
Surgical stress marker patterns in IBD 
Figure 8 demonstrates the surgical stress response according to the levels of the main 
inflammatory biomarkers. The concentration of TNF-α peaked 6 hours after surgical 
incision, decreased after 24 hours, and then exhibited a plateau at 48 hours. Similar 
patterns were observed for the IL-6, IL-8, IL-10, IL-17A, WBC, D-dimer, ferritin and 
transferrin concentrations and the IL-6/IL-10 ratio. While the CRP concentration 
peaked 48 hours after surgical incision. The TNF-α/IL-10 and TNF-α/cortisol ratios 
decreased at 6 hours, began to increase at 24 hours, and reached a plateau at 48 hours. 
A significant stress response over time (p<0.01) was found for all biomarkers except 
TNF-α, IL-17A and cortisol. 
Differences in the surgical stress response between the two groups 
The patients treated with anti-TNF-α agents tended to show higher concentrations of 
most inflammatory biomarkers compared with the anti-TNF-α-naïve patients, as 
shown in figure 9. This difference was more pronounced in the patients with 
detectable drug concentrations and no anti-drug antibodies. However, the differences 
were not significant (figure 9). 
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Subgroup analyses 
Subgroup analysis was performed by selecting patients who underwent laparoscopic 
ileocecal/ileocolic resection (12/46) to obtain a homogenous group of patients who 
had undergone the same type of surgical procedure. Comparing the anti-TNF-α-
treated and anti-TNF-α-naïve patients in this subgroup showed no significant 
difference in the surgical stress response (results not shown). 
Postoperative outcome 
No difference in the adjusted analyses of the rates of overall complications (27.8% 
versus 28.6%), superficial SSI (7.8% versus 7.1%), IASC (5.6% versus 7.1%) or 
readmission (22.2% versus 25%) were found between the two groups. The mean LOS 
in the anti-TNF-α-treated and anti-TNF-α-naïve groups were 5.33 days (± 2.57) and 
6.25 days (± 3.01), respectively, but this difference was not significant. 
4.1.2 LIMITATIONS 
The main limitations of this study include the small sample size, the heterogeneity of 
the patient population and the included surgical interventions. The administration of 
steroids at the induction of anaesthesia and the use of postoperative epidural analgesia 
in some of the included patients might have affected the results.  
    Figure 8: Surgical stress response in 46 patients with inflammatory bowel disease who 
underwent surgical intervention as part of disease treatment. The main 
immunological biomarkers of stress are shown. The figure shows that the surgical 
stress response peaked 6 hours after the surgical incision. 
    The box shows the medians and inter-quartile ranges, and the numbers above the box 
show the concentrations of the outliers. 
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    Figure 9: Surgical stress response in patients treated with anti-TNF-α agents and in 
anti-TNF-α-naïve patients. The figure shows only the main immunological biomarkers 
of stress (TNF-α, IL-6, IL-8, IL-10, IL-6/IL-10 ratio). The box shows the medians and 
inter-quartile ranges, and the numbers above the box show the concentrations of the 
outliers 
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Table 6: Type of anti-TNF-α agent, duration of treatment, drug concentration and presence of anti-drug 
antibodies. 
Type Dose Last anti-TNF-α dose 
before surgery 
(weeks) 
Drug 0 Drug 6 
hours 
Drug 
24 
hours 
Drug 
48 
hours 
Anti-drug 
antibodies 
ADA 80 2 0.65 0.65 0.65 0.65 Negative 
ADA 40 3 8.49 7.33 7.09 6.13 Positive 
ADA 40 2 4.25 3.86 3.48 3.73 Negative 
ADA 40 1 17.65 16.27 14.42 15.71 Negative 
ADA 40 1 2.06 1.41 1.75 0.65 Negative 
ADA 40 3 0.65 0.65 0.65 0.65 Negative 
ADA 40 1 0.65 0.65 0.65 0.65 Negative 
ADA 100 2 2.89 1.34 1.74 1.37 Negative 
IFX 300 3 31.00 7.29 15.32 12.95 Negative 
IFX 330 2 4.48 4.36 3.56 3.44 Negative 
IFX 100 9 0.65 0.65 0.65 0.65 Positive 
IFX 100 9 0.65 0.65 0.65 0.65 Negative 
IFX 350 1 31.00 31.00 21.38 21.94 Negative 
IFX 290 8 0.65 0.65 0.65 0.65 Negative 
IFX 450 8 0.65 0.65 0.65 0.65 Positive 
IFX 800 5 17.28 14.17 14.45 15.21 Negative 
Golimumab 50 5 1.39 1.06 1.13 0.99 Negative 
Combinatio
n 
700 4 8.05 4.90 5.07 4.58 Negative 
Drug 0: drug concentration (µg/ml) before surgery. Drug 6: drug concentration (µg/ml) 6 hours after 
surgery. Drug 24: drug concentration (µg/ml) 24 hours after surgery. Drug 48: drug concentration (µg/ml) 
48 hours after surgery. 
A concentration of 0.65 µg/ml refers to undetectable drug concentrations (shadowed). The techniques used 
for the measurement of anti-drug antibodies are described at the laboratory website 
(http://www.wieslab.com/diagnostic-ervices/index.php?langId=1&headId=72&subId=143&pageId=195). 
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5. DISCUSSION 
The four studies included in this Ph.D. project show that the effect of anti-TNF-α 
treatment on the postoperative outcome is due to the interplay of many factors, of 
which steroid treatment, drug concentration, and the presence/absence of anti-drug 
antibodies are particularly important.  
The relationship of anti-TNF-α therapy to postoperative outcome in patients with CD 
has been investigated in 30 retrospective cohorts80,81,90–98,107,82,108–117,83–89, two 
prospective cohorts118,119, four experimental studies120–123, one population-based 
study124, one prospective international multi-centre snapshot audit54, five narrative 
reviews99,100,125–127 and eight meta-analyses79,101–105,128,129 over the last 15 years. In 
addition to retrospective studies that investigated this issue as one of several possible 
risk factors for unfavourable postoperative outcome, this group of studies includes 
studies that focused on UC patients and studies that focused on patients with 
rheumatoid arthritis. In fact, the effect of anti-TNF-α therapy on postoperative 
outcome has been the subject of more than 72 scientific papers published in the last 
15 years. 
Thirteen of the 28 retrospective studies80,81,90–93,82–89 were discussed and analysed in 
depth in study 279. The recently published retrospective studies did not show 
differences in methodology, and the authors of these studies were unable to reach 
decisive conclusions. However, two of these studies deserve attention. Waterman et 
al.96 examined a large series of patients exposed to anti-TNF-α agents (195 patients 
were matched and compared to 278 controls) and recorded the concentrations of the 
anti-TNF-α drug and anti-drug antibodies over an extended period of exposure (180 
days before and after abdominal surgery). These researchers found that anti-TNF-α 
agents did not increase the risk of postoperative complications even when the patients 
were divided into subgroups that included only patients with detectable blood 
concentrations. The conclusion presented by Lau et al.107 was completely different. 
Lau et al. included 150 patients treated with anti-TNF-α agents within a cohort of 217 
patients. Half of the anti-TNF-α-treated patients had undetectable drug concentrations 
in their blood 7 days prior to surgical intervention. For patients with CD, no 
differences in the postoperative outcomes of the treated and control patients and in the 
outcomes of the patients with detectable and undetectable blood drug concentrations 
were found. However, an analysis using a cut-off level of 3 μg/ml for the anti-TNF-α 
drug concentration revealed that postoperative morbidity (OR = 2.5, p = 0.03) and 
infectious complications (OR = 3.0, p = 0.03) were significantly higher in the ≥ 3 
μg/ml group, and higher rates of postoperative morbidity (p = 0.047) and hospital 
readmissions (p = 0.04) were observed in the ≥ 8 μg/mL group compared with the < 
3 μg/mL group. The study included only 21% of the patients who underwent surgery 
during the study period and failed to adjust for many confounders, including the 
inclusion of patients with undetectable concentrations of anti-TNF-α and untreated 
patients130. 
 
 
57 
 
Attempts to use prospective nationwide cohorts did not fulfil the hope of reaching 
decisive conclusions because the two prospective studies reached two diverging 
conclusions118,119. The study conducted by Fumery et al. included 209 patients, of 
whom 93 were treated with anti-TNF-α within 3 months prior to surgery, and the anti-
TNF-α drug concentrations were measured in only 76 of the 93 patients who received 
anti-TNF-α within 3 months prior to surgery. The authors concluded that treatment 
with anti-TNF-α was not a risk factor for postoperative complications even in patients 
who had blood drug concentrations greater than ≥ 3 μg/ml. However, the drug 
concentration was measured over a wide time window of 3 months after the last anti-
TNF-α dose in only a portion of the cohort. 
Brouguet et al.118 found that treatment with anti-TNF-α increases the risk of 
postoperative complications. The study did not adjust for disease severity, which is a 
crucial confounding factor in this group of patients because the patients who received 
anti-TNF-α agents might have been those who did not respond to stepwise treatment 
beginning with 5-ASA, steroids and immunomodulation and escalating to anti-TNF-
α. These patients might have suffered from ongoing inflammation and/or a poor 
nutritional status (the latter was not assessed using a nutritional index), and neither 
the drug concentration at the time of surgery nor the level of anti-drug antibodies was 
measured in the study. Thus, the above-mentioned conclusion is questionable. 
Only a few studies reported the rates of proximal faecal diversion by means of 
protective loop ileostomies126.  
From this perspective, the current literature on CD is complicated by small-sample-
size studies with selection bias and heterogeneity in the definition of anti-TNF-α 
exposure, the outcome timeline, the definition of infectious/non-infectious 
complications, and the types of surgeries performed. The current literature does not 
report the combined effect of other potential confounding factors for unfavourable 
postoperative outcome, such as disease severity/extent, nutritional status, smoking, 
preoperative drug concentration of anti-TNF-α agents and the presence of anti-drug 
antibodies61,126. Few studies reported the Clavien-Dindo classification of 
postoperative complications, making it difficult to compare the results. Moreover, 
anastomotic leak was either not defined or different definitions were used in the 
studies in which anastomotic leak rates were reported. 
The aim of this Ph.D. thesis was to generate evidence that can be implemented in 
evidence-based medicine (EBM). EBM is the conscientious, explicit and judicious 
use of the current best evidence in making decisions regarding the care of individual 
patients131. The question of the impact of anti-TNF-α treatment on postoperative 
outcome was investigated in a retrospective observational study (study 1). However, 
observational studies might have conflicting results, as shown in studies 2 and 3, in 
which the published trials were critically appraised. Despite attempts to control bias, 
many confounding factors that can only be resolved by an RCT or a prospective trial 
of robust design persist.  
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Randomization of the patients selected to receive anti-TNF-α therapy followed by 
surgery in one arm and anti-TNF-α therapy without surgery in the other arm would be 
the best method for investigating the postoperative outcome in patients with CD. 
However, this protocol is both impractical and unethical because it would result in 
some patients undergoing major surgical intervention even though they respond to 
medical treatment alone, and other patients may require early surgical intervention. 
Second, the timing of randomization and the choice of when to administer 
preoperative anti-TNF-α therapy can be difficult. Third, the participation of patients 
in such studies will be limited by the desire of most patients to avoid surgery. These 
and other practical difficulties have discouraged researchers from conducting RCTs 
on this subject.  
When an RCT is not feasible, an array of robust techniques can be used in an attempt 
to replicate the randomization process by creating a control group that is essentially 
equivalent to the treatment group with respect to known pre-intervention 
characteristics and assuming that the remaining unknown characteristics will not bias 
the results. One of these techniques is propensity score matching, which is defined as 
the probability of assigning a patient to the treatment group conditional on observed 
covariates (Rosenbaum & Rubin, 1983); this technique controls for pre-intervention 
differences between the treated and non-treated groups. Although these methods can 
never ensure the level of validity that could be achieved in an RCT, they are 
considered robust alternatives when randomization is impractical132. This technique 
was implemented in study 4 to analyse the impact of anti-TNF-α treatment on the 
concentrations of biomarkers of the surgical stress response. Measurements of the 
drug levels and antibody status was another feature of study 4. 
The maintenance of detectable serum anti-TNF-α trough levels is vital for retaining 
clinical and endoscopic remission in CD133. In the case of a lack of response or a 
diminishing response to anti-TNF-α agents, the trough level in combination with the 
anti-TNF-α antibody status might help clinicians make appropriate decisions 
regarding escalating doses or switching therapies134. This was evident in study 4, 
which showed that patients who received anti-TNF-α treatment within 12 weeks had 
varying blood drug concentrations and that these varied with respect to the presence 
of anti-drug antibodies. A repeated measurement of the concentration of the anti-TNF-
α drug and anti-drug antibodies prior to the operation and 6, 24 and 48 hours after the 
time of surgical incision revealed no significant changes in the drug concentration or 
anti-drug antibody levels despite the observed changes in immunological biomarkers. 
This result has an important implication for future studies because it shows that a 
single preoperative measurement of the drug concentration and anti-drug antibody 
levels at the induction of anaesthesia or within 48 hours of the operation is sufficient 
for investigating the effect of anti-TNF-α treatment on postoperative outcome.  
The dose of the anti-TNF-α agent and the time interval between the last dose and 
surgical intervention were not reflected in the drug concentration or in the presence 
or absence of anti-drug antibodies (study 4). Although this finding is not novel, it 
might nevertheless explain the divergent results of previous studies that reported the 
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dose of anti-TNF-α and/or the time interval between the last dose and surgical 
intervention (few studies reported the drug concentration). The withdrawal of anti-
TNF-α agents might be guided by measurements of the drug concentrations and anti-
drug antibody levels. However, the withdrawal of anti-TNF-α therapy must be 
weighed against the potential negative effects of gaps in therapy, including 
immunogenicity and flare of disease. Further research is needed to identify specific 
groups of patients who may benefit from drug withdrawal. 
 
Although the implementation of the different methodological settings used in the four 
studies included in this Ph.D. thesis could be considered a limitation, it is also a 
strength. The studies reflected a maturation of scientific thinking: the analyses and 
exploration complemented each other, resulting in study 4, which, despite being an 
exploratory study with a small sample size that involved heterogeneous surgical 
procedures for CD and UC, contributes to our understanding of the clinical problem 
and provides a helpful basis for the design of future studies. The lessons learned from 
studies 1-3 were used in study 4, in which adjustments for all known confounding 
factors were made based on the extensive literature on the subject. The most important 
of these factors include disease severity, nutritional status, smoking, the use of 
concomitant immunosuppressive therapy and the surgeon performing the operation 
(two surgeons in each centre). The preoperative optimization and the use of 
anaesthetics, steroids and NSAIDs were documented in details. The protocol was 
published at clinicaltrials.gov, and complications were defined in the study protocol 
and classified according to the Clavien-Dindo classification of surgical complications.  
The implementation of robust statistical methods (study 4) required close cooperation 
with a statistician, and repeated measurements of the anti-TNF-α, anti-drug antibody 
and surgical stress biomarker levels required close cooperation with biochemists and 
specialized laboratories. This design indeed reflects a maturation of the scientific 
approach and reveals the complexity of the clinical question.  
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6. CONCLUSIONS AND IMPLICATIONS 
The effect of anti-TNF-α therapy on the postoperative outcome in patients with CD 
reflects the interplay of many factors. The most important of these factors include 
concomitant steroid therapy, disease severity, nutritional status, smoking, 
preoperative optimization, the preoperative drug blood concentration levels and the 
presence of anti-drug antibodies. The preoperative withdrawal of anti-TNF-α is not 
supported by the current evidence; however, a multi-centre RCT is needed to confirm 
or disprove this recommendation. To solve the ethical and practical problems 
associated with RCTs, randomization should take place when patients on anti-TNF-α 
therapy need surgical intervention. 
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7. PERSPECTIVES 
An RCT in which patients with CD who are receiving anti-TNF-α therapy are 
randomized to either experience the withdrawal or the continuation of anti-TNF-α 
therapy prior to elective ileocaecal/ileocolic resection or hemicolectomy is needed. 
Such an RCT would make it possible to determine the effect of anti-TNF-α therapy 
on the postoperative outcome. A large sample size, preoperative measurements of the 
drug concentration and anti-drug antibody levels, and a systematic assessment of the 
disease severity, nutritional status and preoperative optimization are mandatory for 
such a study. These considerations will require international multi-centre cooperation 
over many years because not all CD patients need surgical intervention, a small 
fraction of those who require surgical intervention receive preoperative anti-TNF-α 
therapy, and an even smaller fraction of patients undergo ileocaecal/ileocolic resection 
and hemicolectomy.  
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